PHARMAC is seeking feedback on a proposal involving 17 products, resulting from a provisional agreement with Novartis New Zealand Limited. The proposal includes the funding of new products and changes relating to other currently funded products.

A separate consultation is also underway involving fingolimod (which is included in the provisional agreement to which this consultation relates) and other multiple sclerosis treatments.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-08-07-multiproduct/